Exploring the JNJ stock price predictions for 2025, 2026, 2030 and so on. To know how the stock will perform in the upcoming years, read the complete technical and fundamental analysis report.
What is JNJ?
Johnson & Johnson, a multinational corporation, operates in the pharmaceuticals, medical devices, and consumer goods sectors. With over 250 subsidiaries spanning approximately 60 countries, it trades on the New York Stock Exchange under the symbol “JNJ”.
Its consumer products range from baby care to skincare and oral care. Notable offerings include Band-Aid, Clean and Clear, and Neutrogena.
The company’s medical devices division produces items for orthopedics, surgery, and vision care, while its pharmaceutical arm focuses on treatments for infectious, metabolic, and cardiovascular diseases, along with oncology and neuroscience.
Established in 1886 with 14 employees, it pioneered sterile surgical products and introduced Johnson’s Baby Soap in 1921.
Over the years, it has acquired over 40 companies, including DePuy in 1998, Synthes in 2012, and Actelion Pharmaceuticals in 2017. Notable subsidiaries include Janssen Pharmaceutica and Neutrogena. In 2019, its subsidiary Ethicon acquired Auris Health for $3.4 billion.
J&J has received numerous awards, including Best Leadership Teams in 2020, and has consistently ranked among the world’s largest public companies, placing 34th on Forbes’ list and 35th on the Fortune 500 in 2020.
Company Profile
| Headquarters | One Johnson and Johnson Plaza, New Brunswick, New Jersey |
| Company type | Public |
| Traded as | NYSE: JNJ |
| ISIN | US4781601046 |
| Industry | Pharmaceutical, Medical Technology |
| Founded | January 1886; 138 years ago in New Brunswick, New Jersey, United States |
| Founders | Robert Wood Johnson I, James Wood Johnson, Edward Mead Johnson |
| Key people | Joaquin Duato (Chairman & CEO) |
| Products | List of Johnson & Johnson products and services |
| Revenue | US$85.16 billion |
| Operating income | US$21.21 billion |
| Net income | US$35.15 billion |
| Total assets | US$167.6 billion |
| Total equity | US$68.78 billion |
| Number of employees | 134,400 |
| Subsidiaries | Abiomed, Acclarent, Actelion, Cilag, DePuy Synthes, Ethicon, Janssen Biotech, Janssen Pharmaceuticals, Janssen Vaccines, Johnson & Johnson Vision, Mentor, Synthes |
| Website | jnj.com |
JNJ Fundamental Analysis
| Market Cap | $388.05B |
| P/B Ratio | 5.6 |
| P/E Ratio | 11 |
| Div. Yield | 2.92% |
| Book Value | $28.23 |
| EPS(TTM) | 13.61 |
| ROE | 47.10% |
| Enterprise Value | $395.52B |
JNJ Stock Price Chart Analysis
JNJ Stock Price Prediction 2025, 2026, 2030, 2040, 2050
JNJ Stock Price Prediction 2025
| Year | JNJ Stock Price Prediction 2025 |
|---|---|
| 2025 | $190 to $255 |
- Analyst Estimates: Analysts generally hold a positive outlook for JNJ in 2025. The average analyst price target sits around $198.85, which represents a potential increase of 13.93% from the current price. Estimates range widely, though, with some analysts predicting a high of $255 and a low of $190.
- Company Guidance: Johnson & Johnson itself has forecasted operational sales growth of 5.5% to 6.5% for 2024, translating to a revenue range of $88.2 billion to $89 billion.
Also Read: SBI Share Price Target 2025, 2030, 2040, 2050
JNJ Stock Price Prediction 2026
| Year | JNJ Stock Price Prediction 2026 |
|---|---|
| 2026 | $260 to $350 |
Forecasts vary significantly. Some analysts, like Gov Capital, are bullish with a target of $350 by year-end 2026. Others, like Wallet Investor, take a more cautious approach, predicting a modest increase from around $260.90 at the beginning to $350.19 by the close of 2026.
Also Read: MULN Stock Forecast 2025, 2030: Is Muln Dead?
JNJ Stock Price Prediction 2030
| Year | JNJ Stock Price Prediction 2030 |
|---|---|
| 2030 | $550 to $735 |
JNJ itself offers long-term growth projections of 5% to 7% annually from 2025 to 2030. This translates to a potential market capitalization range of $500 billion to $980 billion by 2030, depending on market valuation
Also Read: Palo Alto Share Price Prediction 2024, 2025 to 2030
Johnson & Johnson Stock Strengths and Weakness
Strengths
- The company demonstrates a high EBITDA/Sales ratio, leading to strong margins before depreciation, amortization, and taxes.
- It consistently achieves among the highest margins on the stock exchange, generating substantial profits from its core activities.
- With a solid financial position, the company has significant flexibility for investment opportunities.
- Analyst sentiment has notably improved over the past four months.
- There is clear visibility into the company’s future activities, with analysts forecasting similar revenue outlooks, contributing to highly predictable sales for both the current and upcoming fiscal years.
- Analysts’ price targets are closely aligned, indicating confidence in the company’s valuation.
Weakness
- Forecast indicates sluggish sales growth in the next fiscal years.
- Potential for earnings per share (EPS) growth in the coming years is perceived as limited based on current analyst estimates.
- The company’s enterprise value to sales ratio, currently at 4.24 times its current sales, is considered high.
- Relative to the value of its tangible assets, the company’s valuation appears elevated.
- Sales expectations for the last twelve months have been significantly revised downward, suggesting lower sales volumes for the current fiscal year compared to the previous period.
- The company’s earnings releases frequently fall short of expectations.
Also Read: Amazon stock forecast 2025, 2030, 2040, 2050
JNJ Q4 Earnings
FAQs
When Does JNJ stock price might hit $500?
JNJ stock price expected to hit $500 in 2029-30.
When does JNJ stock price hit $1000?
Expected to hit the targeted price in 2033-35.
Will Johnson & Johnson Be a Trillion-Dollar Stock by 2030?
Predicting JNJ hitting $1 trillion by 2030 is uncertain. The pharmaceutical industry’s growth and JNJ’s focus on innovation could fuel a climb, but competition and market volatility present challenges.
